Silence Therapeutics plc
SLN098
Obesity
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for SLN098 in Obesity are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“SANRECO Ph2 topline results Divesiran Polycythemia Vera SLN098 Obesity”